Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes

European Journal of Pharmacology

Volumn 361, Issue 1, 1998, Pages 143-149

  Yamamoto, Atsuko ^a   Hoshi, Katsuji ^a   Ichihara, Kazuo ^a  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Fluvastatin; Free radical scavenger; HMG CoA reductase inhibitor; Lipid peroxidation

Indexed keywords

BUTYLCRESOL; FLUINDOSTATIN; FREE RADICAL; HYDROXYL RADICAL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; PRAVASTATIN; PROBUCOL; SUPEROXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; XANTHINE; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; LIPID PEROXIDATION; LIVER MICROSOME; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; BUTYLATED HYDROXYTOLUENE; CYTOCHROME P-450 ENZYME SYSTEM; FATTY ACIDS, MONOUNSATURATED; FREE RADICAL SCAVENGERS; HYDROXYL RADICAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIPID PEROXIDATION; MALE; MICROSOMES, LIVER; PRAVASTATIN; PROBUCOL; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDES;

EID: 0031783925     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00692-X     Document Type: Article

References (34)

1. Afanas'ev I.B., Dorozhko A.I., Polozova N.I., Kuprianova N.S., Brodskii A.V., Ostrachovitch E.A., Korkina L.G. Is superoxide an initiator of microsomal lipid peroxidation? Arch. Biochem. Biophys. 302:1993;200-205.
2. Bestervelt L.L., Vaz A.D.N., Coon M.J. Inactivation of ethanol-inducible cytochrome P-450 and other microsomal P-450 isozymes by trans-4-hydroxy-2-nonenal, a major product of membrane lipid peroxidation. Proc. Natl. Acad. Sci. USA. 92:1995;3764-3768.
3. Davis H.W., Suzuki T., Schenkman J.B. Oxidation of esterified arachidonate by rat liver microsomes. Arch. Biochem. Biophys. 252:1987;218-228.
4. Ernster, L., Nordenbrand, K., Orrenius, S., 1982. Microsomal lipid peroxidation: mechanism and some biomedical implications, In: Yagi, K. (Eds.), Lipid Peroxides in Biology and Medicine. Academic Press, New York and London, pp. 55-79.
5. Finkelstein E., Rosen G.M., Rauckman E.J. Spin trapping of superoxide and hydroxyl radical: practical aspects. Arch. Biochem. Biophys. 200:1980;1-16.
6. Gotoh N., Niki E. Rates of interactions of superoxide with vitamin E, vitamin C and related compounds as measured by chemiluminescence. Biochim. Biophys. Acta. 1115:1992;201-207.
7. Gotoh N., Niki E. Measurement of superoxide reaction by chemiluminescence. Methods in Enzymology. 233:1994;154-160.
8. Harber F., Weiss J. The catalytic decomposition of hydrogen peroxide by iron salts. Proc. R. Soc. London. Ser. A. 147:1934;332-351.
9. Hiramatsu M., Liu J., Edamatsu R., Ohba S., Kadowaki D., Mori A. Probucol scavenged 1,1-diphenyl-2-picrylhydrazyl radicals and inhibited formation of thiobarbituric acid reactive substances. Free Radic. Biol. Med. 16:1994;201-206.
10. Hoffman R., Brook G.J., Aviram M. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis. 93:1992;105-113.
11. Hoshi K., Senda N., Fujino S. Acute effect of amitriptyline, phenobarbital or cobaltous chloride on δ-aminolevulinic acid synthetase, heme oxygenase and microsomal heme content and drug metabolism in rat liver. Japan J. Pharmacol. 50:1989;289-293.
12. Hu Y., Mishin V., Johansson I., Bahr C., Cross A., Ronis M.J.J., Badger T.M., Ingelman-Sundberg M. Chlormethiazole as an efficient inhibitor of cytochrome P450 2E1 expression in rat liver. J. Pharmacol. Exp. Ther. 269:1994;1286-1291.
13. Hussein O., Schlezinger S., Rosenblat M., Keidar S., Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis. 128:1997;11-18.
14. Ingelman-Sundberg, M., 1986. Cytochrome P-450 organization and membrane interactions. In: Montellano, P.R.O. (Ed.), Cytochrome P-450. Plenum Press, New York, pp. 119-160.
15. Jordan R.A., Schenkman J.B. Relationship between malondialdehyde production and arachidonate consumption during NADPH-supported microsomal lipid peroxidation. Biochem. Pharmacol. 31:1982;1393-1400.
16. Karuzina I.I., Archakov A.I. Hydrogen peroxide-mediated inactivation of microsomal cytochrome P450 during monooxygenase reactions. Free Radic. Biol. Med. 17:1994;557-567.
17. Koga T., Simada Y., Kuroda M., Tsujita Y., Hasegawa K., Yamazaki M. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim. Biophys. Acta. 1045:1990;115-120.
18. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
19. Nakamura M. Lactoferrin-mediated formation of oxygen radicals by NADPH-cytochrome P-450 reductase system. J. Biochem. 107:1990;395-399.
20. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95:1979;351-358.
21. Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem. 239:1964;2370-2378.
22. Ottolenghi A. Interaction of ascorbic acid and mitochondrial lipides. Arch. Biochem. Biophys. 79:1959;355-363.
23. Phillips A.H., Langdon R.G. Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. J. Biol. Chem. 237:1962;2652-2661.
24. Puntarulo S., Cederbaum A.I. Role of cytochrome P-450 in the stimulation of microsomal production of reactive oxygen species by ferritin. Biochim. Biophys. Acta. 1289:1996;238-246.
25. Rifici V.A., Khachadurian A.K. Oxidation of high density lipoproteins: characterization and effects on cholesterol efflux from J774 macrophages. Biochim. Biophys. Acta. 1299:1996;87-94.
26. Rudling M., Collins V.P. Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels are coordinately reduced in human renal cell carcinoma. Biochim. Biophys. Acta. 1299:1996;75-79.
27. Satoh K., Yamamoto A., Nakai T., Hoshi K., Ichihara K. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. Br. J. Pharmacol. 116:1995;1894-1898.
28. Thompson D.C., Cha Y., Trush M.A. The peroxidase-dependent activation of butylated hydroxyanisole and butylated hydroxytoluene (BHT) to reactive intermediates. J. Biol. Chem. 264:1989;3957-3965.
29. TB (CYP2C9) by (±)-fluvastatin. Clin. Pharmacol. Ther. 58:1995;412-417.
30. Transon C., Leemann T., Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol. 50:1996;209-215.
31. Valoti M., Sipe H.J., Sgaragli G., Mason R.P. Free radical intermediates during peroxidase oxidation of 2-t-butyl-4-methoxyphenol, 2,6-di-t-butyl-4-methylphenol, and related phenol compounds. Arch. Biochem. Biophys. 269:1989;423-432.
32. Winterbourn C.C. The ability of scavengers to distinguish ·OH production in the iron-catalyzed Haber-Weiss reaction: Comparison of four assays of ·OH. Free Radic. Biol. Med. 3:1987;33-39.
33. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88:1991;1785-1792.
34. Yamamoto A., Itoh S., Hoshi K., Ichihara K. Inhibition of cholesterol synthesis ex vivo and in vivo by fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Experientia. 51:1995;223-226.